Main Menu
Main Menu
This website uses cookies that help the website function and that help us understand how you interact with it. Please read our privacy policy for more information.
The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a complete surgical removal of stage IIIb/c/d or stage IV Melanoma
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 12 Years and Over |
| Gender | All |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT03068455 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
Bristol-Myers Squibb |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Bristol-Myers Squibb |
| Principal Investigator Affiliation | Bristol-Myers Squibb |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
| Overall Status | Active, not recruiting |
| Countries | Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Greece, Israel, Italy, New Zealand, Poland, Romania, Russian Federation, Spain, Switzerland, United Kingdom, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Melanoma |
| Study Website: | View Trial Website |
Experimental: nivolumab + ipilimumab
Specified Dose on Specified Days
Experimental: nivolumab
Specified Dose on Specified Days
Biological: - nivolumab
Specified Dose on Specified Days
Biological: - ipilimumab
Specified Dose on Specified Days
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
University of Arizona Cancer Center
Tucson, Arizona, 85724
Status
Address
The Angeles Clinic & Research Institute
Los Angeles, California, 90025
Status
Address
California Pacific Medical Center
San Francisco, California, 94115
Status
Address
University Of Colorado
Aurora, Colorado, 80045
Status
Address
Georgetown University Med Ctr
Washington, District of Columbia, 20007
Status
Address
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140
Status
Address
UF Health Cancer Center at Orlando Health
Orlando, Florida, 32806
Status
Address
Winship Cancer Institute
Atlanta, Georgia, 30322
Status
Address
Northwestern University
Chicago, Illinois, 60611
Status
Address
University Of Chicago
Chicago, Illinois, 60637
Status
Address
Oncology Specialists, S.C.
Park Ridge, Illinois, 60068
Status
Address
Mass General Hospital
Boston, Massachusetts, 02114
Status
Address
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Status
Address
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Status
Address
University Of Michigan Health System
Ann Arbor, Michigan, 48109-5848
Status
Address
Virginia Piper Cancer Institute
Minneapolis, Minnesota, 55407
Status
Address
Mayo Clinic Rochester
Rochester, Minnesota, 55905
Status
Address
Washington University School Of Medicine
Saint Louis, Missouri, 63110
Status
Address
NYU Langone Medical Center
New York, New York, 10016
Status
Address
Memorial Sloan Kettering Nassau
New York, New York, 10065
Status
Address
Carolinas Med Ctr
Charlotte, North Carolina, 28204
Status
Address
Duke University Medical Center
Durham, North Carolina, 27710
Status
Address
Providence Cancer Center Oncology And Hematology Care
Portland, Oregon, 97213
Status
Address
Oregon Health & Science University
Portland, Oregon, 97239
Status
Address
St. Luke's University Health Network
Easton, Pennsylvania, 18045
Status
Address
Local Institution
Nashville, Tennessee, 37232
Status
Address
Texas Oncology Sammons Cancer Center
Dallas, Texas, 75246
Status
Address
Md Anderson Can Cnt
Houston, Texas, 77030-4009
Status
Address
Huntsman Cancer Institute
Salt Lake City, Utah, 84112
Status
Address
University Of Virginia Health System
Charlottesville, Virginia, 22908
Status
Address
Inova Melanoma and Skin Cancer Center
Fairfax, Virginia, 55905
Status
Address
University Of Washington Cancer Care Alliance
Seattle, Washington, 98109-1023
Status
Address
Local Institution
North Sydney, New South Wales, 2060
Status
Address
Local Institution
Waratah, New South Wales, 2298
Status
Address
Local Institution
Westmead, New South Wales, 2145
Status
Address
Local Institution
Greenslopes, Queensland, 4120
Status
Address
Local Institution
Southport, Queensland, 4215
Status
Address
Local Institution
Woolloongabba, Queensland, 4120
Status
Address
Local Institution
Adelaide, South Australia, 5000
Status
Address
Local Institution
Box Hill, Victoria, 3128
Status
Address
Local Institution
Melbourne, Victoria, 3000
Status
Address
Local Institution
Melbourne, Victoria, 3004
Status
Address
Local Institution
Nedlands, Western Australia, 6009
Status
Address
Local Institution
Subiaco, Western Australia, 6008
Status
Address
Local Institution
Graz, , 8036
Status
Address
Local Institution
Wien, , 1090
Status
Address
Local Institution
Brussels, , 1090
Status
Address
Local Institution
Bruxelles, , 1200
Status
Address
Local Institution
Gent, , B-9000
Status
Address
Local Institution
Liege, , 4000
Status
Address
Local Institution
Salvador, Bahia, 41950-610
Status
Address
Local Institution
Belo Horizonte, Minas Gerais, 30130-090
Status
Address
Local Institution
Ijui, RIO Grande DO SUL, 98700-000
Status
Address
Local Institution
Porto Alegre, RIO Grande DO SUL, 90610-000
Status
Address
Local Institution
Florianopolis, Santa Catarina, 88034-000
Status
Address
Local Institution
Barretos, SAO Paulo, 14780-070
Status
Address
Local Institution
Sao Jose do Rio Preto, SAO Paulo, 15090-000
Status
Address
Local Institution
Rio De Janeiro, , 20220-410
Status
Address
Local Institution
Rio de Janeiro, , 22793-080
Status
Address
Local Institution
Sao Paulo, , 01246-000
Status
Address
Local Institution
Edmonton, Alberta, T6G 1Z2
Status
Address
Local Institution
Vancouver, British Columbia, V5Z 4E6
Status
Address
Local Institution
Ottawa, Ontario, K1H 8L6
Status
Address
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9
Status
Address
Local Institution
Montreal, Quebec, H2L 4M1
Status
Address
Local Institution
Montreal, Quebec, H3T 1E2
Status
Address
CHU de Quebec - Universite Laval
Quebec, , G1R 2J6
Status
Address
Klinika komplexni onkologicke pece
Brno, , 656 53
Status
Address
Klinika onkologie a radioterapie
Hradec Kralove, , 500 05
Status
Address
Dermatovenerologicka klinika 3. LF UK a FNKV
Praha 10, , 100 34
Status
Address
Dermatovenerologicka klinika VFN a 1. LF UK
Praha 2, , 128 08
Status
Address
Centre Hospitalier Universitaire Dijon Bocage
Dijon, , 21079
Status
Address
Hopital Claude Huriez
LILLE Cedex, , 59037
Status
Address
Hopital De La Timone
Marseille Cedex 5, , 13385
Status
Address
Chu Nantes
Nantes, , 44093
Status
Address
Hopital Saint Louis
Paris, , 75475
Status
Address
Centre Hospitalier Lyon Sud
Pierre Benite Cedex, , 69495
Status
Address
Institut Claudius Regaud
Toulouse Cedex 9, , 31059
Status
Address
Institut Gustave Roussy
Villejuif, , 94805
Status
Address
Local Institution
Berlin, , 10117
Status
Address
Local Institution
Buxtehude, , 21614
Status
Address
Local Institution
Essen, , 45147
Status
Address
Local Institution
Gera, , 07548
Status
Address
Local Institution
Hannover, , 30625
Status
Address
Local Institution
Heidelberg, , 69120
Status
Address
Local Institution
Luebeck, , 23538
Status
Address
Local Institution
Muenchen, , 80337
Status
Address
Local Institution
Tuebingen, , 72076
Status
Address
Laiko Hospital
Athens, , 11527
Status
Address
Metropolitan Hospital
Athens, , 18547
Status
Address
Local Institution
Haifa, , 3109601
Status
Address
Local Institution
Jerusalem, , 91120
Status
Address
Local Institution
Tel Hashomer, , 52621
Status
Address
ASST Papa Giovanni XXIII
Bergamo, , 24127
Status
Address
Ospedale Policlinico San Martino
Genova, , 16132
Status
Address
IRCCS Istituto Nazionale Tumori Milano
Milano, , 20133
Status
Address
Istituto Nazionale Tumori Fondazione Pascale
Napoli, , 80131
Status
Address
Istituto Oncologico Veneto IOV
Padova, , 35128
Status
Address
Azienda Ospedaliera Universitaria Senese
Siena, , 53100
Status
Address
Local Institution
Tauranga, BAY OF Plenty, 3143
Status
Address
Local Institution
Christchurch, ,
Status
Address
Local Institution
Dunedin, , 9001
Status
Address
Klinika Nowotworow Ukladowych i Uogolnionych
Krakow, , 31-115
Status
Address
Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
Warszawa, , 02-781
Status
Address
Institute Of Oncology "Prof.Dr.Alexandru Trestioreanu" Bucha
Bucharest, , 022328
Status
Address
Sf. Nectarie Oncology Center
Craiova, , 200347
Status
Address
Local Institution
Krasnodar, , 350040
Status
Address
Local Institution
Krasnoyarsk, , 660133
Status
Address
Local Institution
Moscow, , 115478
Status
Address
Hospital Universitari Germans Trias I Pujol
Badalona-barcelona, , 08916
Status
Address
H. Univ. Vall dHebron
Barcelona, , 08035
Status
Address
Hospital Clinic I Provincial
Barcelona, , 08036
Status
Address
Hospital Gral. Univ. Gregorio Maranon
Madrid, , 28007
Status
Address
Hospital Regional Universitario De Malaga
Malaga, , 29010
Status
Address
Hosp Univ Virgen Macarena
Sevilla, , 41009
Status
Address
Hospital Universitario Y Politecnico La Fe
Valencia, , 46026
Status
Address
Local Institution
Lausanne, , 1011
Status
Address
Local Institution
Zurich, , 8091
Status
Address
Local Institution
Oxford, Oxfordshire, OX3 7LJ
Status
Address
The Beatson West Of Scotland Cancer Centre
Glasgow, , G12 0YN
Status
Address
The Royal Marsden Hospital
London, , SW3 6JJ
Status
Address
Christie Hospital Nhs Trust
Manchester, , M20 4BX
Status
Address
Royal Marsden Hospital - Surrey
Sutton., , SM25PT
